Literature DB >> 19329943

Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas.

Susann Karlberg1, Marita Lipsanen-Nyman, Heini Lassus, Jukka Kallijärvi, Anna-Elina Lehesjoki, Ralf Butzow.   

Abstract

Mulibrey nanism is an autosomal recessive growth disorder caused by mutations in the TRIM37 gene encoding a protein of unknown function. More than half of female patients with Mulibrey nanism develop benign mesenchymal tumors of ovarian sex cord-stromal origin. In this work, we characterize the gynecological tumors of female patients with Mulibrey nanism in detail. In addition to tumors of the fibrothecoma group, 18% (4/22) of the patients were observed with epithelial neoplasias, including 2 ovarian adenofibromas, 1 ovarian poorly differentiated adenocarcinoma and 1 endometrial adenocarcinoma. To investigate the possible involvement of TRIM37 alterations in the pathogenesis of sporadic fibrothecomas, we analyzed the TRIM37 cDNA for mutations and alternatively spliced transcripts and TRIM37 expression in fibrothecomas of women without Mulibrey nanism. No mutations in the open-reading frame of TRIM37 were detected. Two alternatively spliced variants were found, one lacking exon 23 and one exon 2. TRIM37del2 was also found in normal ovary but in a proportion of sporadic fibrothecomas, the TRIM37del2:TRIM37 ratio was increased. In normal ovary, TRIM37 was localized in the cytoplasm of stromal cells, especially theca cells surrounding developing follicles. TRIM37 transcript was found in all sporadic fibrothecomas examined, but 80% (20/25) of the tumors showed reduced or absent expression of TRIM37 protein. Allelic loss at the TRIM37 locus (17q22-23) was observed in 6% of sporadic fibrothecomas. Nearly half of the sporadic fibrothecomas showed evidence of CpG promoter methylation, suggesting promoter downregulation as one mechanism of reduced TRIM37 expression. In conclusion, inherited biallelic inactivation of TRIM37 (Mulibrey nanism) predisposes to both mesenchymal and epithelial ovarian tumors and dysregulation of TRIM37 may also be involved in the pathogenesis of sporadic fibrothecomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329943     DOI: 10.1038/modpathol.2009.13

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  9 in total

1.  TRIM37 promoted the growth and migration of the pancreatic cancer cells.

Authors:  Jianxin Jiang; She Tian; Chao Yu; Meiyuan Chen; Chengyi Sun
Journal:  Tumour Biol       Date:  2015-09-22

Review 2.  TRIM37: a critical orchestrator of centrosome function.

Authors:  Andrés Domínguez-Calvo; Pierre Gönczy; Andrew J Holland; Fernando R Balestra
Journal:  Cell Cycle       Date:  2021-10-21       Impact factor: 5.173

Review 3.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

4.  TRIM37 prevents formation of condensate-organized ectopic spindle poles to ensure mitotic fidelity.

Authors:  Franz Meitinger; Dong Kong; Midori Ohta; Arshad Desai; Karen Oegema; Jadranka Loncarek
Journal:  J Cell Biol       Date:  2021-05-13       Impact factor: 10.539

5.  TRIM37 promotes epithelial‑mesenchymal transition in colorectal cancer.

Authors:  Cheng-En Hu; Jun Gan
Journal:  Mol Med Rep       Date:  2017-01-16       Impact factor: 2.952

6.  Silencing TRIM37 inhibits the proliferation and migration of non-small cell lung cancer cells.

Authors:  Yi Ding; Yi Lu; Xinjie Xie; Bo Sheng; Zuopei Wang
Journal:  RSC Adv       Date:  2018-10-31       Impact factor: 3.361

7.  Liver pathology and biochemistry in patients with mutations in TRIM37 gene (Mulibrey nanism).

Authors:  Johanna Sivunen; Susann Karlberg; Reetta Kivisaari; Jouko Lohi; Niklas Karlberg; Eero Jokinen; Taisto Sarkola; Timo Jahnukainen; Marita Lipsanen-Nyman; Hannu Jalanko
Journal:  Liver Int       Date:  2022-03-08       Impact factor: 8.754

8.  Origin and diversification of TRIM ubiquitin ligases.

Authors:  Ignacio Marín
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

9.  Trim37-deficient mice recapitulate several features of the multi-organ disorder Mulibrey nanism.

Authors:  Kaisa M Kettunen; Riitta Karikoski; Riikka H Hämäläinen; Teija T Toivonen; Vasily D Antonenkov; Natalia Kulesskaya; Vootele Voikar; Maarit Hölttä-Vuori; Elina Ikonen; Kirsi Sainio; Anu Jalanko; Susann Karlberg; Niklas Karlberg; Marita Lipsanen-Nyman; Jorma Toppari; Matti Jauhiainen; J Kalervo Hiltunen; Hannu Jalanko; Anna-Elina Lehesjoki
Journal:  Biol Open       Date:  2016-05-15       Impact factor: 2.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.